Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMS Adamas Pharmaceuticals	$8.22	$8.17	$4.02 ▼ $9.15	$376.37M	2.82	692,487 shs	N/A
AGRX Agile Therapeutics	$1.51	$1.49	$0.20 ▼ $2.63	$10.35M	1.58	352,864 shs	120,938 shs
MBIO Mustang Bio	$2.18 -6.0%	$1.48	$0.89 ▼ $24.00	$10.16M	2.16	1.62 million shs	373,533 shs
NCNA NuCana	$0.05 +1.9%	$0.07	$0.03 ▼ $10.79	$280K	1.42	50.70 million shs	66.54 million shs
XERS Xeris Biopharma	$5.11 -2.3%	$4.79	$2.10 ▼ $6.07	$817.89M	0.66	2.07 million shs	1.48 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMS Adamas Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
AGRX Agile Therapeutics	0.00%	0.00%	0.00%	0.00%	+4.86%
MBIO Mustang Bio	+4.98%	-13.43%	+127.45%	+74.44%	-87.36%
NCNA NuCana	-6.77%	-21.61%	-62.14%	-94.56%	-98.48%
XERS Xeris Biopharma	-0.57%	-0.76%	+15.20%	+27.25%	+113.47%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AGRX Agile Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MBIO Mustang Bio	0.9261 of 5 stars	0.0	5.0	0.0	0.0	2.1	0.0	0.6
NCNA NuCana	3.2206 of 5 stars	3.3	3.0	0.0	0.0	2.9	2.5	1.3
XERS Xeris Biopharma	4.0027 of 5 stars	2.4	3.0	0.0	4.2	3.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMS Adamas Pharmaceuticals	0.00	N/A	N/A	N/A
AGRX Agile Therapeutics	0.00	N/A	N/A	N/A
MBIO Mustang Bio	0.00	N/A	N/A	N/A
NCNA NuCana	2.50	Moderate Buy	$25.00	52,310.90% Upside
XERS Xeris Biopharma	2.83	Moderate Buy	$6.25	22.31% Upside

Current Analyst Ratings Breakdown

Latest XERS, NCNA, AGRX, ADMS, and MBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/9/2025	XERS Xeris Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$6.00 ➝ $7.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMS Adamas Pharmaceuticals	$74.46M	5.05	N/A	N/A	($0.47) per share	-17.49
AGRX Agile Therapeutics	$19.98M	0.52	N/A	N/A	($5.51) per share	-0.27
MBIO Mustang Bio	N/A	N/A	N/A	N/A	($2.11) per share	N/A
NCNA NuCana	N/A	N/A	N/A	N/A	$1.34 per share	N/A
XERS Xeris Biopharma	$203.07M	3.94	N/A	N/A	($0.20) per share	-25.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMS Adamas Pharmaceuticals	-$57.40M	-$1.70	N/A	N/A	N/A	-71.11%	N/A	-42.96%	N/A
AGRX Agile Therapeutics	-$14.47M	-$3.65	N/A	∞	N/A	-36.24%	N/A	-147.37%	N/A
MBIO Mustang Bio	-$15.75M	-$78.00	0.00	N/A	N/A	N/A	N/A	-80.79%	8/12/2025 (Estimated)
NCNA NuCana	-$24.28M	-$7.02	0.00	N/A	N/A	N/A	-319.85%	-88.55%	8/13/2025 (Estimated)
XERS Xeris Biopharma	-$54.84M	-$0.30	N/A	N/A	N/A	-20.25%	N/A	-12.07%	8/6/2025 (Estimated)

Latest XERS, NCNA, AGRX, ADMS, and MBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	XERS Xeris Biopharma	-$0.03	N/A	N/A	N/A	N/A	N/A
6/2/2025	Q1 2025	NCNA NuCana	-$0.0129	-$0.63	-$0.6171	-$0.63	N/A	N/A
5/14/2025	Q1 2025	MBIO Mustang Bio	N/A	-$0.05	N/A	-$0.05	N/A	N/A
5/8/2025	Q1 2025	XERS Xeris Biopharma	-$0.07	-$0.06	+$0.01	-$0.06	$57.61 million	$57.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AGRX Agile Therapeutics	N/A	N/A	N/A	N/A	N/A
MBIO Mustang Bio	N/A	N/A	N/A	N/A	N/A
NCNA NuCana	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMS Adamas Pharmaceuticals	21.25	4.53	4.17
AGRX Agile Therapeutics	N/A	0.56	0.38
MBIO Mustang Bio	N/A	1.34	1.34
NCNA NuCana	N/A	1.25	1.25
XERS Xeris Biopharma	N/A	1.72	1.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMS Adamas Pharmaceuticals	69.97%
AGRX Agile Therapeutics	10.92%
MBIO Mustang Bio	9.95%
NCNA NuCana	44.00%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
ADMS Adamas Pharmaceuticals	18.90%
AGRX Agile Therapeutics	0.50%
MBIO Mustang Bio	0.21%
NCNA NuCana	31.20%
XERS Xeris Biopharma	6.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMS Adamas Pharmaceuticals	138	45.79 million	37.13 million	Optionable
AGRX Agile Therapeutics	30	6.86 million	6.82 million	Not Optionable
MBIO Mustang Bio	100	4.38 million	4.37 million	Not Optionable
NCNA NuCana	30	6.08 million	4.18 million	Not Optionable
XERS Xeris Biopharma	290	156.38 million	146.27 million	Optionable

XERS, NCNA, AGRX, ADMS, and MBIO Headlines

Recent News About These Companies

CenterBook Partners LP Cuts Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

July 16 at 10:32 AM | marketbeat.com

Brown Advisory Inc. Has $630,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

July 15 at 4:13 AM | marketbeat.com

Xeris Biopharma Holdings, Inc. (XERS) - Yahoo Finance

July 10, 2025 | finance.yahoo.com

Xeris Biopharma (NASDAQ:XERS) Trading 7.4% Higher - Time to Buy?

July 9, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Rating of "Moderate Buy" from Analysts

June 28, 2025 | marketbeat.com

Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing

June 18, 2025 | seekingalpha.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Kevin Mcculloch Buys 25,000 Shares

June 17, 2025 | insidertrades.com

Xeris Biopharma touts ambitious growth plan, promising hypothyroidism drug

June 4, 2025 | chicagobusiness.comC

Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day

June 3, 2025 | finance.yahoo.com

Xeris Announces Details for Analyst & Investor Day

May 20, 2025 | businesswire.com

Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now

May 12, 2025 | msn.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Earnings Call Transcript

May 10, 2025 | insidermonkey.com

Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...

May 9, 2025 | finance.yahoo.com

Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Xeris Biopharma Reports Record First Quarter 2025 Financial Results

May 8, 2025 | businesswire.com

4XERS : Earnings Outlook For Xeris Biopharma Holdings

May 7, 2025 | benzinga.com

Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings

May 7, 2025 | seekingalpha.com

Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

May 2, 2025 | seekingalpha.com

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To Profit

April 26, 2025 | finance.yahoo.com

Is Xeris Biopharma Holdings Inc. (XERS) the Best Multibagger Penny Stock to Buy According to Billionaires?

April 22, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS, NCNA, AGRX, ADMS, and MBIO Company Descriptions

Adamas Pharmaceuticals NASDAQ:ADMS

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Agile Therapeutics NASDAQ:AGRX

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Mustang Bio NASDAQ:MBIO

$2.18 -0.14 (-6.03%)

Closing price 04:00 PM Eastern

Extended Trading

$2.19 +0.01 (+0.69%)

As of 07:54 PM Eastern

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

NuCana NASDAQ:NCNA

$0.05 +0.00 (+1.92%)

Closing price 04:00 PM Eastern

Extended Trading

$0.05 0.00 (-0.84%)

As of 07:59 PM Eastern

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Xeris Biopharma NASDAQ:XERS

$5.11 -0.12 (-2.29%)

Closing price 04:00 PM Eastern

Extended Trading

$5.12 +0.00 (+0.10%)

As of 07:52 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time